Introduction. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as an important therapeutic option in type 2 diabetes mellitus, with proven cardiovascular and renal benefits. However, their use has been linked to rare cases of euglycemic diabetic ketoacidosis (euDKA), a potentially life-threatening complication characterized by metabolic acidosis and ketosis in the absence of marked hyperglycemia. This risk may be heightened in patients with latent autoimmune diabetes in adults (LADA), an autoimmune form of diabetes often misclassified as type 2 diabetes due to its slow progression.
Case presentation. We report the case of a 60-year-old woman initially diagnosed with type 2 diabetes and treated with metformin and dapagliflozin. Shortly after starting SGLT2i therapy, she developed severe euDKA requiring hospitalization. Laboratory evaluation revealed metabolic acidosis, positive ketone bodies, and near-normal blood glucose. Autoimmune testing confirmed the diagnosis of LADA, with elevated antibodies against glutamic acid decarboxylase (anti- GAD) and low C-peptide levels. This case not only reflects the diagnostic complexity of LADA, but also raises concern regarding the possible contribution of SGLT2 inhibitors to precipitating ketoacidosis, particularly in patients with unrecognized insulin deficiency. While SGLT2i therapy offers significant clinical benefits, careful patient selection is critical. Screening for pancreatic autoantibodies may help identify patients at higher risk and prevent adverse outcomes.
Conclusions. The clinicians should consider autoimmune diabetes in atypical cases and remain vigilant for signs of euDKA when prescribing SGLT2 inhibitors. Structured screening and close monitoring may improve patient safety without compromising the therapeutic advantages of this drug class.
Keywords: SGLT2 inhibitor, euglycemic ketoacidosis, LADA, anti-GAD antibodies.
How to cite Email to Author
Address for correspondence:
Felicia DARII
“Nicolae Testemitanu” State University of Medicine and Pharmacy and
Institute of Cardiology, Chisinau, Republic of Moldova
Email: felicia.darii@usmf.md; Phone +37369434463